KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Share-based Compensation (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Share-based Compensation data on record, last reported at $2.7 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 31.67% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $12.7 million, up 2.57%, while the annual FY2025 figure was $12.7 million, 2.57% up from the prior year.
  • Share-based Compensation reached $2.7 million in Q4 2025 per RIGL's latest filing, down from $3.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $5.1 million in Q1 2024 and bottomed at $1.9 million in Q4 2023.
  • Average Share-based Compensation over 5 years is $2.8 million, with a median of $2.6 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: plummeted 52.62% in 2023, then skyrocketed 86.15% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $2.3 million in 2021, then skyrocketed by 74.43% to $4.1 million in 2022, then tumbled by 52.62% to $1.9 million in 2023, then increased by 7.97% to $2.1 million in 2024, then soared by 31.67% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $2.7 million in Q4 2025, $3.4 million in Q3 2025, and $3.3 million in Q2 2025.